Australia's 4DMedical soars on US reimbursement for CT:VQ; Bell Potter raises valuation

Shares of Australia's 4Dmedical 4DX.AX surge as much as 37% to A$1.055, highest since late November, 2023

Medical technology co top gainer on the ASX All Ordinaries index .AORD

Says U.S. Centers for Medicare & Medicaid Services (CMS) confirms reimbursement for its CT:VQ technology, which is used for lung-imaging

Adds CT:VQ scans will be reimbursed by CMS at $650.50 per scan

Analysts at Bell Potter raise their valuation to A$1.05 apiece from A$0.70, and retain a "buy" rating

Brokerage notes 4DX's pulmonary embolism assessment technology could potentially displace nuclear medicine

Co's tech likely to gain traction if hospital revenues are boosted with reimbursement - Bell Potter

YTD, stock has more than doubled in value